Myers Scott Dunseth

Chief Executive Officer at VRDN

Sold, on record
None
Dollars the filings state
Form 4 sales
0
None on record
Form 144 notices
1
Proposed sales
Quarters with a sale
0 of the last 8
No sale in two years
Companies
1
Filed as an executive or holder

Companies

  • VRDNViridian Therapeutics, Inc.\DEChief Executive Officer

Sales by reason

No Form 4 sale on record for Myers Scott Dunseth.

Timeline

  1. Nov 16, 2023Notice

    VRDN

    Filed a notice to sell 35,368 shares

    $535k35,368 shares

    Filed Nov 16, 2023Form 144

1 of 1

Every transaction

Every transaction on a Form 4 or Form 5 by Myers Scott Dunseth
TradedFiledStockRoleWhatAmountPriceValueHeld afterSource
Jun 16, 2026Jun 18, 2026ZNTLDirectorAwarded57,100395,895SEC
Feb 10, 2026Feb 10, 2026DYNAVAX TECHNOLOGIES CORPDirectorTendered3,8000SEC
Feb 10, 2026Feb 10, 2026DYNAVAX TECHNOLOGIES CORPDirectorReturned to the companyStock Option (Right to Buy)135,3750SEC
Feb 10, 2026Feb 10, 2026DYNAVAX TECHNOLOGIES CORPDirectorReturned to the company31,2040SEC
Aug 22, 2025Aug 25, 2025DYNAVAX TECHNOLOGIES CORPDirectorBought3,800$10.82$41k35,004SEC
Jun 17, 2025Jun 18, 2025ZNTLDirectorAwarded57,603338,795SEC
Jun 11, 2025Jun 13, 2025DYNAVAX TECHNOLOGIES CORPDirectorAwardedStock Option (Right to Buy)28,50028,500SEC
Jun 11, 2025Jun 13, 2025DYNAVAX TECHNOLOGIES CORPDirectorAwarded5,75831,204SEC
Apr 30, 2025Apr 30, 2025ZNTLDirectorBought21,000$1.40$29k281,192SEC
Nov 13, 2024Nov 13, 2024ZNTLDirectorAwarded260,192260,192SEC
May 23, 2024May 28, 2024DYNAVAX TECHNOLOGIES CORPDirectorAwardedStock Option (Right to Buy)22,50022,500SEC
May 23, 2024May 28, 2024DYNAVAX TECHNOLOGIES CORPDirectorAwarded5,35725,446SEC
Mar 11, 2024Mar 11, 2024Harpoon Therapeutics, Inc.DirectorReturned to the companyDirector Stock Option (Right to Buy)6,6330SEC
Mar 11, 2024Mar 11, 2024Harpoon Therapeutics, Inc.DirectorReturned to the company22,6650SEC
Jan 1, 2024Jan 3, 2024Harpoon Therapeutics, Inc.DirectorAwarded2,04822,666SEC
Nov 27, 2023Nov 28, 2023Harpoon Therapeutics, Inc.DirectorAwarded5,00020,618SEC
Nov 13, 2023Nov 15, 2023RNACDirectorReturned to the companyStock Option (Right to Buy)207,500$0.39$81k0SEC
Oct 1, 2023Oct 2, 2023Harpoon Therapeutics, Inc.DirectorAwarded5,79715,618SEC
Jul 1, 2023Jul 6, 2023Harpoon Therapeutics, Inc.DirectorAwarded35,63498,215SEC
Jun 22, 2023Jun 23, 2023Harpoon Therapeutics, Inc.DirectorAwardedDirector Stock Option (Right to Buy)46,00046,000SEC
May 26, 2023May 31, 2023DYNAVAX TECHNOLOGIES CORPDirectorAwardedStock Option (Right to Buy)22,50022,500SEC
May 26, 2023May 31, 2023DYNAVAX TECHNOLOGIES CORPDirectorAwarded5,35720,089SEC
Apr 12, 2023Apr 12, 2023VRDNChief Executive OfficerBought4,000$25.37$101k259,500SEC
Apr 1, 2023Apr 4, 2023Harpoon Therapeutics, Inc.DirectorAwarded34,92562,581SEC
Mar 13, 2023Mar 13, 2023VRDNChief Executive OfficerBought5,500$29.15$160k255,500SEC
Feb 6, 2023Feb 7, 2023VRDNChief Executive OfficerAwardedStock Option (Right to Buy)1M1MSEC
Feb 6, 2023Feb 7, 2023VRDNChief Executive OfficerAwarded250,000250,000SEC
Jan 2, 2023Jan 4, 2023RNACDirectorAwardedStock Option (Right to Buy)87,50087,500SEC
Jun 22, 2022Jun 24, 2022Harpoon Therapeutics, Inc.DirectorAwardedDirector Stock Option (Right to Buy)20,33420,334SEC
May 26, 2022May 27, 2022DYNAVAX TECHNOLOGIES CORPDirectorAwardedRestricted Stock Unit20,89316,875SEC
Jan 3, 2022Jan 5, 2022RNACDirectorAwardedStock Option (Right to Buy)40,00040,000SEC
Nov 17, 2021Nov 19, 2021Trillium Therapeutics Inc.DirectorReturned to the companyStock Option (Right to Buy)67,0000SEC
Oct 25, 2021Oct 26, 2021Harpoon Therapeutics, Inc.DirectorAwardedDirector Stock Option (Right to Buy)10,16710,167SEC
Oct 19, 2021Oct 21, 2021DYNAVAX TECHNOLOGIES CORPDirectorAwardedRestricted Stock Unit55,71445,000SEC
May 4, 2021May 7, 2021Harpoon Therapeutics, Inc.DirectorAwardedDirector Stock Option (Right to Buy)10,16710,167SEC
May 3, 2021May 5, 2021Trillium Therapeutics Inc.DirectorAwardedStock Option (Right to Buy)67,00067,000SEC
Mar 30, 2021Apr 1, 2021RNACDirectorAwardedStock Option (Right to Buy)40,00040,000SEC
Nov 16, 2020Nov 17, 2020ADVANCED MAGNETICS INCPresident & CEOReturned to the companyStock Option (Right to Buy)1M0SEC
Jun 19, 2020Jun 23, 2020RNACDirectorAwardedStock Option (Right to Buy)20,00020,000SEC
May 28, 2020Jun 1, 2020Harpoon Therapeutics, Inc.DirectorAwardedDirector Stock Option (Right to Buy)10,16710,167SEC
Apr 28, 2020Apr 30, 2020ADVANCED MAGNETICS INCPresident & CEOAwardedStock Option (Right to Buy)1M1MSEC
Dec 23, 2019Dec 26, 2019RNACDirectorAwardedWarrants19,704$0.13$3k19,704SEC
Dec 23, 2019Dec 26, 2019RNACDirectorAwarded39,409$1.46$58k80,845SEC
Aug 20, 2019Aug 20, 2019RNACDirectorAwarded41,436$1.81$75k41,436SEC
Jun 14, 2019Jun 18, 2019RNACDirectorAwardedStock Option (Right to Buy)20,00020,000SEC
Jun 3, 2019Jun 5, 2019Harpoon Therapeutics, Inc.DirectorAwardedDirector Stock Option (Right to Buy)10,16710,167SEC
Mar 9, 2018Mar 13, 2018Oncothyreon Inc.President and CEOTendered56,7870SEC
Mar 9, 2018Mar 13, 2018Oncothyreon Inc.President and CEOReturned to the companyStock Option (Right to buy)1M0SEC
Feb 1, 2018Feb 2, 2018Oncothyreon Inc.President and CEOAwardedRestricted Share Unit (RSU)250,000250,000SEC
Jan 11, 2018Jan 16, 2018Oncothyreon Inc.President and CEOExercised or settledRestricted Share Unit (RSU)10,50031,500SEC
Page 1

Sales and notices (1)

Form 144 notices and Form 4 sales by Myers Scott Dunseth
Source
Nov 16, 2023Nov 16, 2023VRDNChief Executive OfficerForm 144 notice35,368$535kNoticeSEC